Anupam Rasayan India Ltd Q1 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/2sncrtf4z3sg9bprl73tx33w.pdf

Key Takeaways


Revenue Growth & Drivers

Vishal Thakkar: "There is a strong upward bias on the growth trajectory that we can see here."

Margin Structure & Sustainability

Anand S Desai: "As you are aware that our contract is structured on a cost-plus basis. Now, when I say cost plus, all costs including raw materials, freight, energy, commodities, inventory holding cost, and other overheads are on a passthrough basis."

Fluorination: The Pipeline Opportunity

Vishal Thakkar: "We have identified around 14 new molecules which we are looking at commercializing in the next 2 to 3 years' time period, and this on a potential basis as we had mentioned that we are looking at $220-260 million of revenue on an annual basis when they are fully ramped up."

Working Capital & Inventory

Vishal Thakkar: "If you look at it from an inventory side, we do not have a price risk as well as we do not have volume risk. We know that they are going to offtake in this timeframe and we are comfortable and the customers have clearly communicated to us that we would be acknowledging the cost at which we have acquired."

Tanfac Integration & Expansion


CAPEX & Balance Sheet


Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA margin26–28% on a conservative basis, with upward biasComing quarters
Revenue growth trajectorySimilar to last 2–3 yearsFY23
Fluorination commercialization5 molecules from existing capacityFY23
Fluorination pipeline14 molecules, $220–260 mn annual revenue potential2–3 years
LOI revenue ramp₹450–500 cr annual revenue from 6 moleculesRamping; 2 molecules this year, 2 next year
Inventory daysSignificant reductionBy year-end
ROCE~14% this year is what we are targeting, further upside as assets get utilizedFY23
Solar powerAdditional 5.4 MW, ₹14 cr annual savingsCommissioning by Q2; savings from FY24
Tax rate25–30%FY24 onwards
CAPEX~₹250 cr for LOI monetizationFY23
7 molecules in $10 mn+ list4 existing + 3 new, per customer forecastsFY23

Key Metrics

MetricQ1 FY23
Operating revenue₹306.6 cr, +31% YoY
Total revenues₹297.1 cr, +25% YoY; impacted by negative Other Income from USD borrowing revaluation
EBITDA (incl. other revenues)₹84.5 cr, +30% YoY
EBITDA margin28%, expansion of 112 bps YoY
Profit after tax₹39.7 cr
Life Science segment revenue~₹290 cr, vs ~₹205 cr in Q1 FY22; 95% of total revenue
Other Specialty Chemicals revenue~₹14 cr, vs ~₹29 cr in Q1 FY22
Revenue growth splitFairly divided between volume and price
EBITDA margin guidance26% to 28% on a conservative basis, with upward bias
FY23 CAPEX plan~₹250 cr, brownfield expansion at Jhagadia for LOI demand
LOIs signed (FY22)₹2,620 cr worth, with ~₹450–500 cr annual revenue expected when ramped
Capacity utilization80% to 85%
Japan revenue contribution13% of revenues, up from 1% in 2018
R&D team strength85 professionals, added 8 during the quarter
Pricing mechanism revision60% to 70% of significant contractual revenue moved to 6-monthly pricing
ROCE target~14% for the year
Tax rate expectation (FY24 onwards)25% to 30%
Fluorination molecules identified14 molecules, annual revenue potential of $220–260 million when fully ramped up
Fluorination molecules commercializing this year5 molecules
Molecules in $10+ million list7 molecules (4 from FY22 plus 3 additional)
Top 10 customer concentration (annual)80% to 85% of revenues
Solar power savingsOver ₹10 cr per annum from 12.5 MW plant; combined ₹14 cr per annum from FY24 with additional 5.4 MW
Cash on books~₹200 cr, sufficient for planned FY23 CAPEX
Tanfac stake acquisition cost₹154 cr for 25.8% stake